Skip to main content
. 2020 Apr 28;13:1756286420918088. doi: 10.1177/1756286420918088

Figure 3.

Figure 3.

Meta-analysis forest plots. (A) Meta-analysis of mean difference of change in baseline monthly acute migraine-specific medication days of galcanezumab 120 mg versus placebo and (B) meta-analysis of mean difference of change in baseline monthly acute migraine-specific medication days of galcanezumab 240 mg versus placebo.

(A) Change in baseline monthly acute migraine-specific medication days – Mean difference of galcanezumab 120 mg versus placebo.

(B) Change in baseline monthly acute migraine-specific medication days – Mean difference of galcanezumab 240 mg versus placebo.